Nicola Massey announced as new divisional MD

Quantum Pharma Plc

("Quantum" or the "Group")

Nicola Massey announced as Managing Director of Niche Pharmaceuticals

Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce the appointment of Nicola Massey as the new Managing Director of its Niche Pharmaceuticals Division.

As announced today, the Group has focused its operations into three divisions; Specials, Niche Pharmaceuticals and Medication Adherence. Niche Pharmaceuticals will comprise the Group's existing Colonis, Lamda, and Pern business units. This section of Quantum's business has grown since the time of IPO, and develops and supplies niche licenced pharmaceuticals and medical devices, provides development and regulatory services and out-licenses its products and dossiers to a wide range of potential third parties across Europe.

Nicola joins Quantum with more than 25 years of leadership experience in the pharmaceutical sector, having held global strategic and in-country operational leadership roles driving cross-functional teams to deliver successful launches across the UK and Europe. Previously, Nicola spent nine years at Shire PLC, focusing on speciality and rare diseases, most recently as UK and Ireland Country General Manager overseeing a period of rapid organic growth and multiple acquisitions. Nicola joins Quantum with a strong reputation in the industry having served on the Association of the British Pharmaceutical Industry (ABPI) Board of Management for two years, specialising in representing the interests of both companies and patients requiring access to medicines for rare and niche conditions.

Nicola Massey, Managing Director, Niche Pharmaceuticals at Quantum Pharma, said: "Quantum has already built a significant pipeline of regulated products to deliver on the next stage of its strategy. I look forward to leading the Niche Pharmaceuticals team as we build on and enhance the capabilities for successful medicine and medical device approvals and launches. I'm delighted to be joining the Group at such an exciting time and I look forward to working with my new colleagues and partners to deliver growth, both within Niche Pharmaceuticals, and across the wider Group."

Andrew Scaife, Chief Executive of Quantum commented: "I would like to welcome Nicola to the team; her knowledge of the development process, pharmaceutical sector and her extensive experience of launching products in both the UK and in Europe will be highly beneficial to the Group. Having implemented the new divisional structure we believe that Nicola's appointment will lay strong foundations for the development of our Niche Pharmaceuticals division as well to Quantum's overall long-term growth."

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials:

Comprising four business units which manufacture, source and supply specials to pharmacies, pharmaceutical wholesalers, hospitals (NHS and private) and other specials suppliers throughout the UK and overseas.

Quantum Pharmaceutical manufactures and supplies specials and special obtains to pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

UL Medicines sources and supplies unlicensed imported medicines, batch made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development and clinical trials product manufacture.

Quantum Aseptic Services manufactures aseptically prepared sterile intravenous products, either individually for named patients or in batches for supply to private and NHS hospitals and homecare patients.

Niche Pharmaceuticals:

Comprising three business units which develop and supply niche pharmaceuticals, provide development and regulatory services and out-license products and dossiers to 3rd parties across Europe.

Colonis® is a product development business which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

Lamda is a full service contract development specialist with customers across Europe. It specialises in creating added value products with distinct advantages for patients and health care providers, providing full services for the entire development chain - from inception to registration, to post approval finished product supply and regulatory support.

PERN Consumer Products, owner of the Dermacool brand - a range of menthol in aqueous creams.

Medication Adherence:

Comprising two business units which provide products and services designed to enhance adherence to medication regimes:

Protomed which owns Biodose® a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. A telehealth version with the ability to remotely monitor medication adherence is in live testing.

Biodose Services® assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.

For further information, please visit www.quantumpharmagroup.com.